Fritextsökning
Innehållstyper
-
Jan Holmgren to receive award for the development of cholera vaccine
Researcher Jan Holmgren is being awarded for the development of the first effective drinkable cholera vaccine. The award is given by the International Vaccine I...
-
Improve Productivity and Accessibility with Award-winning Human-Centered Design
Enhance your workflow with integrated intelligence.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
WuXi AppTec, UK Ltd
-
Superconductor technology: Contactless working in the laboratory of the future
Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo
-
Cleveland Clinic: Kirurgi gav fler långsiktiga fördelar än GLP-1-läkemedel
Metabol kirurgi minskade riskerna för död, hjärtsjukdom, njursvikt och ögonskador mer än GLP-1-läkemedel under en tioårsperiod. Det enligt en ny studie från Cle...
-
A small thing that can solve your problems
If you are in need of a compact valve. Look no further! We have the VOVK
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
FDA approves Gilead’s HIV injection: “Historic day”
Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...
-
New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
Discover the new ZEISS Axioscan 7 clinical
Your digital slide scanner for diagnostics & clinical research.
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...
-
Xbrane enters licensing agreement with Indian generics giant
Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.
-
Will the FDA’s new transparency policy extend to medical devices? (Part 1)
In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...
-
Accelerate your Research with AI-Powered Image Analysis
Comprehensive eBook from ZEISS.
-
Festo Expands its Portfolio with Multilayer Manifolds
Manufacturers of medical and laboratory equipment now receive solutions from a single source
-
How to transport hydrogen - the BionicHydrogenBattery
Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.
-
ZEISS unveils AI-powered Research Data Platform
Collaboration with Boehringer Ingelheim champions the future of personalized eye care.
-
US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee
Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.